Literature DB >> 31250923

Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia.

Sherif M Badawy1, Kerry Morrone, Alexis Thompson, Tonya M Palermo.   

Abstract

BACKGROUND: Thalassemia syndromes are inherited hemoglobin disorders that result when the synthesis of normal hemoglobin is lacking or significantly reduced. For people with thalassemia, long-term red blood cell transfusion remains the mainstay of therapy, which may lead to iron overload causing severe complications and damage in different body organs. Long-term iron chelation therapy is essential for people with thalassemia to minimize the ongoing iron-loading process. In addition, suboptimal adherence can increase adverse events associated with iron overload and result in increased morbidity, mortality, healthcare utilization and cost of care.
OBJECTIVES: To identify and assess the effects of computer and mobile technology interventions designed to facilitate medication adherence and disease management in individuals with thalassemia, including:- evaluating the effects of using computer and mobile technology interventions for medication adherence and disease management on health and behavioral outcomes;- identifying and assessing the effects of computer and mobile technology interventions specific to different age groups (children, adolescents and adults) and type of modality (e.g. cell phone, the Internet). SEARCH
METHODS: We searched CENTRAL (the Cochrane Library), MEDLINE, Embase, CINAHL, PsycINFO, ProQuest Dissertations & Theses Global, Psychology and Behavioral Sciences Collection, Web of Science Science & Social Sciences Conference Proceedings Indexes, IEEE Xplore and ongoing trial databases (22 February 2018). We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group's Haemoglobinopathies Trials Register (20 June 2019). We also searched for unpublished work in the abstract book of nine major conferences in the related field. SELECTION CRITERIA: Randomized controlled trials (RCT) and quasi-RCTs comparing single- or multi-component interventions versus no intervention, placebo or standard care, with adherence to iron chelation as the primary outcome were eligible for inclusion. Non-randomized studies of interventions, controlled before-after studies, and interrupted-time-series studies were also eligible for inclusion. DATA COLLECTION AND ANALYSIS: Three authors independently assessed study eligibility. If we had included any studies, we would have independently assessed risk of bias and extracted data; we planned to assess the quality of the evidence using GRADE. MAIN
RESULTS: We did not identify any eligible studies for inclusion in the review. AUTHORS'
CONCLUSIONS: Due to lack of evidence, we cannot comment on the efficacy or effectiveness of computer and mobile technology intervention strategies to promote disease management and adherence to iron chelation therapy in people with thalassemia.We concluded that RCTs are needed to examine a variety of computer and mobile technology intervention strategies that may be useful for promoting disease management and increasing adherence to iron chelation therapy in individuals with thalassemia.

Entities:  

Mesh:

Year:  2019        PMID: 31250923      PMCID: PMC6598413          DOI: 10.1002/14651858.CD012900.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  66 in total

1.  Social networks and collateral health effects.

Authors:  Nicholas A Christakis
Journal:  BMJ       Date:  2004-07-24

Review 2.  Beta-thalassemia.

Authors:  Deborah Rund; Eliezer Rachmilewitz
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

3.  Result of video-education on "genetic transmission in thalassemia" to thalassemic patients and their parents.

Authors:  Siriorn Paholpak; Arunee Jetsrisuparb; Surapon Wiangnon; Darunee Sangsahachat; La-or Padtawaro
Journal:  J Med Assoc Thai       Date:  2006-11

4.  Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy.

Authors:  M J Treadwell; L Weissman
Journal:  Semin Hematol       Date:  2001-01       Impact factor: 3.851

5.  A simple model to assess and improve adherence to iron chelation therapy with deferoxamine in patients with thalassemia.

Authors:  Zahra Pakbaz; Roland Fischer; Marsha Treadwell; Robert Yamashita; Ellen B Fung; Lisa Calvelli; Keith Quirolo; Drucilla Foote; Paul Harmatz; Elliott P Vichinsky
Journal:  Ann N Y Acad Sci       Date:  2005       Impact factor: 5.691

6.  Compliance assessed by the Medication Event Monitoring System.

Authors:  N F Olivieri; D Matsui; C Hermann; G Koren
Journal:  Arch Dis Child       Date:  1991-12       Impact factor: 3.791

7.  Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia.

Authors:  Maria Domenica Cappellini; Mohamed Bejaoui; Leyla Agaoglu; John Porter; Thomas Coates; Michael Jeng; Maria Eliana Lai; Antonio Mangiagli; Gabriele Strauss; Robert Girot; Nora Watman; Alina Ferster; Sandra Loggetto; Sharon Abish; Holger Cario; Nicolaos Zoumbos; Elliott Vichinsky; Herbert Opitz; Catherine Ressayre-Djaffer; Linda Abetz; Diana Rofail; Jean-Francois Baladi
Journal:  Clin Ther       Date:  2007-05       Impact factor: 3.393

8.  Patient adherence and medical treatment outcomes: a meta-analysis.

Authors:  M Robin DiMatteo; Patrick J Giordani; Heidi S Lepper; Thomas W Croghan
Journal:  Med Care       Date:  2002-09       Impact factor: 2.983

9.  A Java-based electronic healthcare record software for beta-thalassaemia.

Authors:  S Deftereos; C Lambrinoudakis; P Andriopoulos; D Farmakis; A Aessopos
Journal:  J Med Internet Res       Date:  2001 Oct-Dec       Impact factor: 5.428

Review 10.  The impact of iron overload and its treatment on quality of life: results from a literature review.

Authors:  Linda Abetz; Jean-Francois Baladi; Paula Jones; Diana Rofail
Journal:  Health Qual Life Outcomes       Date:  2006-09-28       Impact factor: 3.186

View more
  5 in total

Review 1.  A Systematic Review of Adherence to Immunosuppression among Pediatric Heart Transplant Patients.

Authors:  Keira Nassetta; Tasmeen Hussain; Katheryn Gambetta; Kevin Le; Linda C O'Dwyer; Sherif M Badawy
Journal:  J Cardiovasc Dev Dis       Date:  2022-05-23

2.  Healthcare resource utilization and direct costs of transfusion-dependent thalassemia patients in Dubai, United Arab Emirates: a retrospective cost-of-illness study.

Authors:  Shaikha Alshamsi; Samer Hamidi; Hacer Ozgen Narci
Journal:  BMC Health Serv Res       Date:  2022-03-05       Impact factor: 2.655

3.  Effect of drug use calendar on adherence to iron chelation therapy in young thalassemia patients.

Authors:  Sriwatree Chawsamtong; Arunee Jetsrisuparb; Kirati Kengkla; Siriluk Jaisue
Journal:  Pharm Pract (Granada)       Date:  2022-02-11

Review 4.  Telemedicine in Malignant and Nonmalignant Hematology: Systematic Review of Pediatric and Adult Studies.

Authors:  Aashaka C Shah; Linda C O'Dwyer; Sherif M Badawy
Journal:  JMIR Mhealth Uhealth       Date:  2021-07-08       Impact factor: 4.773

5.  Adherence to Immunosuppression Medications among Heart Transplant Recipients: Challenges, Opportunities, and Potential Role of Digital Approaches in the COVID-19 Era.

Authors:  Tasmeen Hussain; Keira Nassetta; Sherif M Badawy
Journal:  J Cardiovasc Dev Dis       Date:  2021-06-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.